Successful ruxolitinib administration for a patient with steroid-refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review

Dan Tomomasa; Takeshi Isoda; Noriko Mitsuiki; Motoi Yamashita; Aoi Morishita; Takahiro Tomoda; Tsubasa Okano; Akifumi Endo; Takahiro Kamiya; Masakatsu Yanagimachi; Kohsuke Imai; Hirokazu Kanegane; Masatoshi Takagi; Tomohiro Morio

doi:10.1002/ccr3.5242

Successful ruxolitinib administration for a patient with steroid-refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review

Clin Case Rep. 2021 Dec 22;9(12):e05242. doi: 10.1002/ccr3.5242. eCollection 2021 Dec.

Authors

Affiliations

¹ Department of Pediatrics and Developmental Biology Tokyo Medical and Dental University Tokyo Japan.
² Clinical Research Center Tokyo Medical and Dental University Tokyo Japan.
³ Department of Hematology and Oncology Kanagawa Children's Medical Center Yokohama Japan.
⁴ Department of Community Pediatrics, Perinatal and Maternal Medicine Tokyo Medical and Dental University Tokyo Japan.
⁵ Department of Child Health and Development Tokyo Medical and Dental University Tokyo Japan.

Abstract

Idiopathic pneumonia syndrome (IPS) is an acute lung complication observed after the early posthematopoietic stem cell transplantation (HSCT) period. Ruxolitinib was effective for a patient with myelodysplastic syndrome who developed severe IPS after second HSCT. No severe adverse effects were observed. Ruxolitinib may be an alternative choice for HSCT-related IPS.

Keywords: graft‐versus‐host disease; hemophagocytic lymphohistiocytosis; idiopathic pneumonia syndrome; myelodysplastic syndrome; ruxolitinib.

Publication types

Case Reports